Barclays
MRNA icon

Barclays’s Moderna MRNA Stock Holding History

Barclays’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$965K Sell
19,000
-572,200
-97% -$26.7M ﹤0.01% 2785
2025
Q4 		$17.4M Buy
591,200
+419,000
+243% +$11.4M ﹤0.01% 1320
2025
Q3 		$4.45M Buy
172,200
+171,000
+14,250% +$4.77M ﹤0.01% 2298
2025
Q2 		$33.1K Sell
1,200
-153,000
-99% -$4.03M ﹤0.01% 4767
2025
Q1 		$4.37M Buy
154,200
+69,200
+81% +$2.46M ﹤0.01% 2012
2024
Q4 		$3.53M Buy
85,000
+65,000
+325% +$3.11M ﹤0.01% 2458
2024
Q3 		$1.34M Sell
20,000
-252,700
-93% -$23.2M ﹤0.01% 3156
2024
Q2 		$32.4M Buy
272,700
+252,700
+1,264% +$32M 0.01% 766
2024
Q1 		$2.13M Sell
20,000
-138,700
-87% -$14M ﹤0.01% 2507
2023
Q4 		$15.8M Buy
+158,700
New +$13.3M 0.01% 1183
2023
Q2 		– Sell
-265,100
Closed -$40.7M – 4889
2023
Q1 		$40.7M Sell
265,100
-631,700
-70% -$104M 0.02% 551
2022
Q4 		$161M Buy
+896,800
New +$147M 0.07% 196
2022
Q3 		– Sell
-544,700
Closed -$77.8M – 5013
2022
Q2 		$77.8M Buy
+544,700
New +$77.9M 0.05% 268

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays's MRNA Position: Q1 2026 in Review

Barclays reduced its Moderna (MRNA) stake by 40% in Q1 2026, selling an estimated $28.5M and leaving 932,269 shares worth $47.4M. The position accounts for 0.01% of the portfolio, ranked #745.

Barclays first reported a position in MRNA in Q1 2019 and has held it in 29 quarters since. The position peaked at $839M in Q4 2021. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Barclays held 932,269 shares of Moderna worth $47.4M as of Q1 2026.
  • Barclays sold 610,188 Moderna shares in Q1 2026, an estimated $28.5M.
  • Moderna made up 0.01% of Barclays's portfolio in Q1 2026, its #745 holding.
  • Barclays first reported a position in Moderna in Q1 2019 and has held it in 29 quarters since.
  • Barclays's Moderna position peaked at $839M in Q4 2021.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.